NCT01681537View on ClinicalTrials.gov

Lenalidomide Plus Chemotherapy for AML

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

September 30, 2015

Study Completion Date

December 31, 2015

Conditions
Acute Myelogenous Leukemia
Interventions
DRUG

Lenalidomide

DRUG

Mitoxantrone

DRUG

Etoposide

DRUG

Cytarabine

Trial Locations (3)

02114

Massachusetts General Hospital, Boston

02115

Brigham and Women's Hospital, Boston

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
lead

Massachusetts General Hospital

OTHER

NCT01681537 - Lenalidomide Plus Chemotherapy for AML | Biotech Hunter | Biotech Hunter